Entrada Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Entrada Therapeutics (Nasdaq: TRDA) will present at two investor conferences in late 2025. The company said CEO Dipal Doshi will deliver a presentation at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 5:00 p.m. GMT and will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on December 3, 2025 at 12:55 p.m. ET.
Both events will be webcast live via the company’s Investor Relations website at www.entradatx.com, with replays available for 90 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TRDA gained 0.55%, reflecting a mild positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $262M at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences.
Jefferies Global Healthcare Conference in London
Dipal Doshi, Chief Executive Officer, will deliver a company presentation on Tuesday, November 18, 2025, at 5:00 p.m. Greenwich Mean Time in London.
8th Annual Evercore Healthcare Conference
Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 12:55 p.m. Eastern Time in Miami, FL.
Live webcasts will be available on the Investor Relations section of the Company’s website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com
Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When will Entrada Therapeutics (TRDA) present at the Jefferies Global Healthcare Conference?
What is the date and time for Entrada Therapeutics (TRDA) fireside chat at Evercore Healthcare?
Will Entrada Therapeutics (TRDA) provide a live webcast of the conference presentations?
How long will Entrada Therapeutics (TRDA) conference replays be available online?
Where can investors find the Entrada Therapeutics (TRDA) presentation replay after the Jefferies conference?
Who will represent Entrada Therapeutics (TRDA) at the November and December 2025 events?
